BioAdaptives

BioAdaptives Tax Expense

The Income Tax Expense of BioAdaptives (BDPT) as of Oct 25, 2026 is -5,600.00 USD. In the previous year, Income Tax Expense was -4.00 USD — a change of 139,900.00% (lower).

Tax Expense

-5,600.00USD

YoY

139,900.00%

Last updated:

Income Tax Expense of BioAdaptives is 2024 -5,600.00 USD. Income Tax Expense of BioAdaptives was 2023 -4.00 USD. It decreases by 139,900.00% lower compared to the previous year.

The BioAdaptives Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2017
-2,444.00 USD
Jan 1, 2018
500,837.00 USD
Jan 1, 2019
199,319.00 USD
Jan 1, 2020
230,328.00 USD
Jan 1, 2021
272,394.00 USD
Jan 1, 2022
184,549.00 USD
Jan 1, 2023
-4.00 USD
Jan 1, 2024
-5,600.00 USD
The BioAdaptives Tax Expense history
YEARTax ExpenseYoY
-5,600.00USD+139,900.00%
-4.00USD-100.00%
184,549.00USD-32.25%
272,394.00USD+18.26%
230,328.00USD+15.56%
199,319.00USD-60.20%
500,837.00USD-20,592.51%
-2,444.00USD-81,566.67%
3.00USD-98.08%
156.00USD-99.89%
138,262.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Income Tax Expense of BioAdaptives is -5,600.00 USD in 2024.

Income Tax Expense of BioAdaptives changed from -4.00 USD to -5,600.00 USD, representing a 139,900.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's BioAdaptives historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioAdaptives

All Key Metrics — BioAdaptives